The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Open accessAbstract
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration. Liquid biopsy might allow real-time sampling of patients for PD-L1 through the course of the disease. Twenty-four stage IV NSCLC patients included in the Expanded Access Program with Nivolumab were enrolled. Circulating tumor cells (CTCs) were analyzed by CellSearch with anti-human B7-H1/PD-L1 PE-conjugated antibody. PD-L1 expressing CTCs were assessed at baseline, at 3 and 6 months after starting therapy, and correlated with outcome. At baseline and at 3 months of treatment, the presence of CTCs and the expression of PD-L1 on their surface were found associated to poor patients outcome. Nevertheless, the high frequency of PD-L1 expressing CTCs hampered to discriminate the role of PD-L1 in defining prognosis. Conversely although CTCs were found in all patients 6 months after treatment, at this time patients could be dichotomized into two groups based PD-L1 expression on CTCs. Patients with PD-L1 negative CTCs all obtained a clinical benefit, while patients with PD-L1 (+) CTCs all experienced progressive disease. This suggests that the persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130142 · Cited by 447
Lou, Y., Diao, L., Cuentas, E. R. P., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 438
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Frequent expression of PD‐L1 on circulating breast cancer cells
Mazel, M., Jacot, W., Pantel, K., Bartkowiak, K., Topart, D., Cayrefourcq, L., Rossille, D., Maudelonde, T., Fest, T., & Alix-Panabières, C. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.05.009 · Cited by 374
The Art of War: Innate and adaptive immune responses
Dempsey, P. W., Vaidya, S. A., & Cheng, G. (2003) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-003-3180-y · Cited by 190
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer
Ligthart, S. T., Coumans, F. A. W., Bidard, F., Simkens, L. H. J., Punt, C. J. A., de Groot, M. R., Attard, G., Bono, J. S. D., Pierga, J., & Terstappen, L. W. M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067148 · Cited by 105
Evolution of end points for cancer immunotherapy trials
Hoos, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds263 · Cited by 103
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
Dong, Z., Wu, S.-P., Liao, R.-Q., Huang, S., & Wu, Y.-L. L. C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4812-9 · Cited by 91
Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
Hanssen, A., Loges, S., Pantel, K., & Wikman, H. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00207 · Cited by 74
Implications for Clinical Practice and Trial Design
Oeberg, K. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32691-0 · Cited by 74
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
Zhou, Z., Zhan, P., & Song, Y. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.03.02 · Cited by 72
Zhou, F., Jiang, T., Ma, W., Gao, G., Chen, X., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.005 · Cited by 67
The potential of liquid biopsies
Buder, A., Tomuta, C., & Filipits, M. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000267 · Cited by 67
Remón, J., Chaput, N., & Planchard, D. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000263 · Cited by 46
Chakravarti, N., & Prieto, V. G. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.12.10 · Cited by 33
From T cell “exhaustion” to anti-cancer immunity
Verdeil, G., Marraco, S. A. F., Murray, T. J., & Speiser, D. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.007 · Cited by 32
Immunotherapy with Checkpoint Inhibitors for Lung Cancer: Novel Agents, Biomarkers and Paradigms
Monteiro, I., Califano, R., Mountzios, G., & de Mello, R. A. (2016) · Future Oncology · doi:10.2217/fon.15.309 · Cited by 10
Cited by
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., Herbst, R. S., Mok, T. S., Peled, N., Pirker, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.030 · Cited by 660
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Keller, L., & Pantel, K. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0180-2 · Cited by 544
Sanmamed, M. F., Perez-Gracia, J. L., Schalper, K. A., Fusco, J. P., Gonzalez, A., Rodriguez-Ruiz, M. E., Oñate, C., Perez, G., Alfaro, C., Martín-Algarra, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx190 · Cited by 458
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., & Silvestris, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918794630 · Cited by 423
Metadata
- Authors
- Nicolazzo, C., Raimondi, C., Mancini, M., Caponnetto, S., Gradilone, A., Gandini, O., Mastromartino, M., del Bene, G., Prete, A., Longo, F., Cortesi, E., & Gazzaniga, P.
- Venue
- Scientific Reports
- Published
- 2016-08-24
- Volume
- 6
- Issue
- 1
- Pages
- 31726-31726
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2507710416
- Cited by
- 281
- References
- 25
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.